Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study-Reference-Cited by-同舟云学术

Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study

Published:2023-10-30 Issue:8 Volume:23 Page:5129-5138
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Nakamoto Shogo^ORCID,Shien Tadahiko,Itoh Mitsuya,Yamamoto Yutaka,Ohsumi Shozo,Yoshitomi Seiji,Hikino Hajime,Miyoshi Kazuya,Notsu Akifumi,Taira Naruto,Doihara Hiroyoshi,Ikeda Masahiko

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-01230-x.pdf

Reference38 articles.

1. Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018;96:17–24.

2. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.

3. Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J Clin Oncol. 2021;39:3938–58.

4. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.

5. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine;Interdisciplinary Cancer Research;2024